



ASX Announcement

## **Medlab Clinical Ltd to Present at LD Micro 2021 Invitational Conference**

***Presentation on June 8<sup>th</sup>, 2021 at 5:00pm EST***

- **Medlab to present at influential US small-cap investor conference.**
- **Increased exposure aiding to Medlab's globalisation plans**
- **Medlab, one of 180 companies selected to present**

**SYDNEY, June 7, 2021** - Medlab Clinical LTD (ASX: MDC), an Australian Biotech focused on delivery platforms to enhance medicines, announced today that it will be presenting virtually at the upcoming LD Micro Invitational XI event on **Tuesday, June 8<sup>th</sup> at 5:00pm EST / Wednesday, June 9<sup>th</sup> at 7:00am AEST**. Dr Sean Hall, CEO/MD of Medlab, will be giving the presentation.

Dr. Sean Hall, CEO of Medlab, stated "We are thrilled to participate in this conference and for the opportunity to engage with hundreds of US investors. This event will represent our second US Investor engagement in the past month, reflecting our efforts to become more global facing as we mature drug candidates for some of today's biggest healthcare issues."

**Event:** Medlab Presentation at the LD Micro Invitational XI

**Date:** June 8<sup>th</sup>, 2021

**Time:** 5:00pm EST

Please register to watch the presentation [here](#).

**ENDS**

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

### **About Medlab Clinical:**

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain. NanoCelle, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab – better medicines, better patient care**

**Summary of LD Micro Invitational XI Event:**

The 2021 LD Micro Invitational will be held on the Sequire Virtual Events platform on Tuesday, June 8th - Thursday, June 10th, 2021. This three-day, virtual investor conference is expected to feature around 180 companies, presenting for 25 minutes each, as well as several influential keynotes. The first day of this conference will also feature an exceptional one-time event: the LD Micro Hall of Fame. For more information, please visit <http://www.ldmicro.com>.

**Contact:**

Medlab Clinical

Dr. Sean Hall, CEO

[Sean\\_hall@medlab.co](mailto:Sean_hall@medlab.co)

Medlab US Investor Relations

Laine Yonker

[lyonker@edisongroup.com](mailto:lyonker@edisongroup.com)